Titre:
  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Auteur:Dimopoulos, Meletios Athanassios; Oriolo, Anna; Nahi, Hareth; San-Miguel, Jesus; Bahlis, Nizar NJ; Usmani, Saad SZ; Rabinovitch Mahler, N.; ORLOWSKI, Ronald R.C.; Komarnicki, Mieczyslaw; Suzuki, K; Plesner, Torben; Yoon, Sungchul S.C.; Ben Yehuda, Dina; Richardson, Paul P.G.; Goldschmidt, Hartmut; Reece, Donna; Lisby, Steen; Khokhar, Nushmia NZ; O'Rourke, Lisa; Chiu, Charles C.B.; Qin, Xiang; Guckert, Mary; Ahmadi, Tahamtan; Moreau, Pascale; POLLUX Investigators,
Informations sur la publication:The New England journal of medicine, 375, 14, page (1319-1331)
Statut de publication:Publié, 2016
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Aged
Antibodies, Monoclonal -- administration & dosage -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
Dexamethasone -- administration & dosage
Disease-Free Survival
Drug Resistance, Neoplasm
Humans
Kaplan-Meier Estimate
Middle Aged
Multiple Myeloma -- drug therapy -- mortality
Recurrence
Thalidomide -- administration & dosage -- analogs & derivatives
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa1607751
info:pmid/27705267